LCTX

The big shareholder groups in Lineage Cell Therapeutics, Inc. (NYSEMKT:LCTX) have power over the company. Insiders...

SPI Energy (SPI) +56% on entering agreement with Shaanxi Tongjia Automobile.Anavex Life Sciences (AVXL) +36% after completing mid-stage study of lead drug in rare brain development disorder.Organogenesis Holdings (ORGO) +27% on Q3 preliminary results.Huttig Building Products

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that updated interim results from a Phase 1/2a study of its lead product candidate, OpRegen®, a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD), will be presented at the 2020 American Academy of Ophthalmology Annual Meeting (AAO 2020), to be held virtually (November 13-15, 2020). The presentation, "Phase 1/2a Study of Subretinally Transplanted hESC-Derived RPE Cells in Advanced Dry-Form AMD Patients" will be featured as part of the Original Paper Session, OP02V Retina, Vitreous Original Papers on November 15, 2020 between 7:40am to 8:25am Pacific Time by Christopher D. Riemann, M.D., Vitreoretinal Surgeon and Fellowship Director, Cincinnati Eye Institute (CEI) and University of Cincinnati School of Medicine. (abstract number 30063541). In addition, data from Lineage will be shown in a presentation by Allen C. Ho, M.D. FACS, Wills Eye Hospital Attending Surgeon and Director of Retina Research, Professor of Ophthalmology, Thomas Jefferson University, entitled: "Cell Based Therapies and Surgical Strategies for Atrophic Age-Related Macular Degeneration 2020," which is being presented as part of the AAO 2020 Retina Subspecialty Day, on November 13, 2020 at 1:38pm Eastern Time.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, and Cancer Research UK, the world’s leading cancer charity dedicated to saving lives through research, today announced encouraging preliminary results from an ongoing Phase 1 clinical study of VAC2 in non-small cell lung cancer (NSCLC). VAC2 demonstrated remarkably potent induction of immune responses in all patients dosed to date, with high levels of peripheral antigen-specific immunogenicity observed at multiple time points and confirmed by multimer staining. On the basis of these findings, and following completion of the ongoing VAC2 clinical study in NSCLC, Lineage will seek to evaluate VAC2 in combination with therapies considered biologically complementary to VAC2, such as chemotherapy and the immune cell protectant properties offered by anti-PD1 immunotherapy.

Preliminary results from ongoing Phase 1 study of Lineage Cell Therapeutics's ([[LCTX]]) VAC2 in non-small cell lung cancer, demonstrated potent induction of immune responses in all patients dosed to date, with high

Potent Induction of Immune Responses Observed with VAC2 Vaccine Peripheral Antigen-specific Immunogenicity Above 3% Observed at Multiple Timepoints VAC2 Appears Well Tolerated with No Unexpected Adverse

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer, and Brandi L. Roberts, Chief Financial Officer, will be participating in a FORCE

WIXOM, Mich., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced